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METHODOLOGICAL, POLITICAL AND LEGAL ISSUES IN THE ASSESSMENT OF THE 
EFFECTS OF NANOTECHNOLOGY ON HUMAN HEALTH 
ABSTRACT 
Engineered nanomaterials (ENMs) raise questions among the scientific community and public health 
authorities about their potential risks to human health. Studying a prospective cohort of workers exposed 
to ENMs would be considered the gold standard for identifying potential health effects of nanotechnology 
and confirming the “no effect” levels derived from cellular and animal models. However, because only 
small, cross-sectional studies have been conducted in the past 5 years, questions remain about the health 
risks of ENMs. This essay addresses the scientific, methodological, political, and regulatory issues that 
make epidemiologic research in nanotechnology-exposed communities particularly complex. Scientific 
challenges include the array of physicochemical parameters and ENM production conditions, the lack of 
universally accepted definitions of ENMs and nanotechnology workers, and the lack of information about 
modes of action, target organs, and likely dose-response functions of ENMs. Standardization of data 
collection and harmonization of research protocols are needed to eliminate misclassification of exposures 
and health effects. Forming ENM worker cohorts from a combination of smaller cohorts and overcoming 
selection bias are also challenges. National or international registries for monitoring the exposures and 
health of ENM workers would be helpful for epidemiological studies, but the creation of such a registry 
and ENM worker cohorts will require political support and dedicated funding at the national and 
international levels. Public authorities and health agencies should consider carrying out an ENM awareness 
campaign to educate and engage all stakeholders and concerned communities to engage in discussion of 
such a project. 
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METHODOLOGICAL, POLITICAL AND LEGAL ISSUES IN THE ASSESSMENT OF THE 
EFFECTS OF NANOTECHNOLOGY ON HUMAN HEALTH 
INTRODUCTION 
Engineered nanomaterials (ENMs) raise questions among the scientific community and public health 
authorities about their potential risks to human health. Commercial use of ENMs began in the early 2000s, 
and within the subsequent decade they became a topic of concern for health researchers. By 2010, at a 
conference on nanomaterials and worker health,[1] participants recognized the need for epidemiological 
studies or, possibly, exposure registries of persons handling ENMs, to support the responsible development 
of nanotechnologies. Among a few dozen opportunities identified then for epidemiologic studies of 
potentially  exposed workers,[2] only one led to published results.[3] The other studies either were never 
launched or were impeded by difficulties.  
Studying a prospective cohort of workers exposed to ENMs would be ideal for identifying potential 
medium- and long-term health effects of nanotechnology[1] and confirming the “no effect” levels derived 
from cellular, animal, and read-across testing models. However,  there are a large number of commercial 
ENMs and only small, cross-sectional studies of a few of them have been conducted in the past 5 years,[4 
5] leaving many questions about ENM health risks. This essay discusses possible explanations for this 
deficiency by addressing issues that make epidemiologic research in nanotechnology-exposed communities 
particularly complex.  
SCIENTIFIC CHALLENGES RELATED TO THE EMERGENT NATURE OF ENMs AS A 
POTENTIAL OCCUPATIONAL HAZARD 
In principle, epidemiologic investigation of ENM health effects should not be inherently different from that 
of other occupational hazards, but many factors related to ENMs make such studies rather uncommon and 
difficult. For instance, ENMs are both chemical molecules and physical objects with a large hyper-reactive 
4 
 
surface. Most ENMs are relatively new. However, ultrafine particles such as carbon black and amorphous 
silica, which have been used for decades may also coincide with the contemporary definition of ENMs.  
The many physicochemical parameters and production conditions resulting in their high heterogeneity 
sustain the challenges and inconsistencies in identifying, characterizing, and classifying them. Additional 
challenges are posed by the newness of exposure scenarios; questions about biologically relevant metrics, 
biological endpoints, and potential health outcomes; the need for practical instrumentation for exposure 
assessment; and the difficulties in identifying exposed populations in workplaces.[6]  
The lack of universally accepted definitions of “engineered nanomaterial” and “nanotechnology worker” is 
a critical challenge for collecting necessary data, especially if one wishes to include multiple countries and 
regions in a study.[7] The working term Nano-Objects and their Aggregates and Agglomerates (NOAA) 
(see Box 1) has only recently facilitated the recognition of different ENMs as such, whereas the 
nanotechnology workforce is not an explicit employment category and its parameters are difficult to 
ascertain. Because nanotechnology is not an industry in itself but crosses many industry and occupation 
sectors, the nanotechnology workforce varies across countries and regions according to ENM resources, 
research, and regulations.[6]  
One major factor that adds to the complexity of conducting epidemiologic research is the multitude of 
different ENMs, with varying types of toxicity (e.g., direct and indirect genotoxicity, generation of 
oxidative stress, inflammation, immunotoxicity, etc.), dose-response functions, and target organs. Some 
ENMs have been shown to have deleterious health effects in laboratory animals but others have not1.  Also, 
some of the effects have occurred only with extraordinarily large doses that are not representative of worker 
exposures.[8 9] There is still debate as to whether modern scientific knowledge is sufficient to conclude 
that the risks of nano-sized substances require separate toxicological assessment. The lack of information 
about modes of action, target organs, and likely dose-response functions of ENMs adds a serious challenge 
to epidemiologic studies involving nanomaterial workers. 
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Timing is another critical issue. Products containing “novel ENMs” became commercially available in the 
late 1990s. Accordingly, the first potentially exposed workers were and are scientists in academic and 
commercial laboratories, followed by those involved in pilot and start-up operations.[10] For large 
companies, this represents less than 5% of the workforce,[11] that is, from a dozen to a few hundred 
workers.[12 13] Although the general belief is that workers’ involvement in the handling, machining, and 
processing of ENM-containing products is rapidly expanding, there are few confirmative data. There are 
limited data on number of workers involved with handling ENM-containing products for disposal or 
recycling.   
From a practical perspective, epidemiologists face both methodological and organizational challenges 
owing to the lack of standardization of data collection and harmonization of research protocols. These 
challenges hamper the registration of ENM-exposed workers and further pooling of individual company 
cohorts.[14 15] 
METHODOLOGICAL CHALLENGES  
One of the primary challenges of assessing individual ENM exposure involves registration of ENM-
exposed workers on a universal or selective basis. Quantitative methods for personal ENM exposure 
monitoring are only starting to become commonplace, and these methods still place many constraints on 
conducting field research. Constraints include high costs, a lack of validated standardized protocols, and 
limits on detection and quantification.[16-18] Indeed, these issues lead to concerns about exposure 
misclassification as well as the health effects of exposure. Because medium- and long-term effects by 
definition occur only after a relatively long latency period following exposure to ENMs, possibly they are 
only now becoming clinically detectable. The effects known from epidemiological studies of ultrafine 
particles and short-term effects, currently evaluated by means of biomarkers of inflammation or oxidative 
stress, are very common and not specific to ENM.[4 19] Thus, cross-sectional studies using effect 
biomarkers are quite limited for drawing conclusions about the relationship between exposure to ENMs 
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and observed effects, especially when the biomarkers used reflect early biochemical or functional changes 
lacking clinical significance.[4 5 20] Furthermore, co-exposures frequent in the workplace and individual 
lifestyle factors require rigorous assessment to control for potential confounding biases15. Clearly, only a 
longitudinal follow-up of a large number of workers exposed to (the same) ENMs could ultimately resolve 
the question of health risks.[2 14] However, the formation of such cohorts from a combination of smaller 
cohorts raises the concern of uncontrollable heterogeneity of ENMs. The heterogeneity of ENMs and the 
ability to identify cohorts of adequate size with the same or similar exposures are among the greatest 
methodological and practical challenges.  It is likely that this issue could be addressed only by assembling 
cohorts from many companies.  Alternatively, instead of assembling cohorts on the basis of similar 
exposures, it might be useful to base the exposure criteria on the similarity of mechanisms of biologic 
effects (such as oxidative damage and genotoxicity) of different ENMs.[4]  However, assembling a large 
enough group of subjects similarly exposed over time still remains a challenge, even though more is known 
about mechanisms of the different ENMs.  
The creation of ENM worker cohorts also raises the concern of serious selection bias. Selection can take 
place in several ways. For instance, companies with exemplary safety and prevention programs may readily 
agree to participate in epidemiological studies. These companies most likely would be large, economically 
strong, and have resources to dedicate to occupational health surveillance.[6 11] Participation in a health 
surveillance program might, in turn, encourage the company’s commitment to protecting the health of its 
workers. Nevertheless, most large national and international companies declined to participate in such 
surveillance offered by the French EpiNano program.[21] Some of these are complex organizations with a 
regulatory affairs department that scrutinizes every study proposal and thus are not inclined to participate 
in studies. Such companies can also consult at the level of their activity sector and refuse participation 
through their professional or trade associations.[11 22] In contrast, small-scale ENM-production companies 
and start-ups were willing to participate in the EpiNano program, despite limited resources and 
personnel.[21 23 24] It was observed that participation of small companies strongly depends on certain 
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factors related to the employer: its sensitivity toward potential, still unknown risks of ENM; its degree of 
responsibility for its employees; its concern about losing proprietary information; its availability to 
participate; and the social climate in the company.[21]  
Selection could manifest differently in private and public research and development laboratories; public 
research laboratories participated more readily in the EpiNano program.[21] At the individual worker level, 
selection operates very differently and may either reinforce or offset the selection effect observed at the 
company level. For example, because of a perception that the work environment is safe and free of risk, 
nanotechnology workers who have available engineering controls and personal protective equipment will 
likely have little interest in participating in medical or epidemiological surveillance programs.[25] In 
contrast, in companies with insufficient risk management and communication, such studies might be 
supported by worker representatives resulting in relatively high individual participation. According to the 
EpiNano program experience, selection operates much stronger at the company level (only 16% 
participation rate) than at the individual level (99% acceptance of passive follow-up and 42% participation 
in both passive and active follow-up).[21]  
Finally, the healthy worker survivor effect could be an additional methodological issue. In epidemiological 
studies of ENM-exposed communities, the dose–response estimates could be biased if past exposure 
predicts future values of a time-dependent variable, which is a risk factor for survival and also predicts 
subsequent exposure.[26] Although there is a relatively simple solution for controlling the last type of bias 
(for example, by using causal models such as G-estimation[27]), the treatment of selection and 
heterogeneous, small cohorts requires a more complex effort at the political and regulatory level. 
POLITICAL AND REGULATORY CHALLENGES 
All major projects leading to the creation of a national exposure registry and national or international 
cohorts will require political support to mobilize laws and create dedicated funding.[28 29] Exposure 
registries of ENM workers would help in the planning and development of epidemiological studies. 
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However, similar to cohorts, such registries would involve the need to recruit numerous companies, since 
the ENM workforce appears to be widely distributed and of low concentration in any one facility. Because 
such registries are costly, are difficult to maintain, and involve numerous ethical, legal, and social issues, it 
is not clear whether a public health or occupational health case could be made for universal or selective 
registries. This uncertainty is due to the lack of a coherent message on the toxicity of ENMs (partly because 
of the highly diverse universe of potential ENMs). In addition, companies’ concern for not disclosing 
proprietary information is a major hurdle. Several regulatory attempts to create an ENM exposure registry 
have failed at the European level, and access to workplaces is an important barrier in launching human 
studies of the risks of ENMs.[6]   
To counter companies’ possible resistance to participating in epidemiological programs and to sharing the 
information necessary for characterizing exposure to ENMs and identifying exposed workers, public 
authorities and health agencies need to engage companies in active discussions as well as carry out an ENM 
awareness campaign. This would communicate state-of-the-art information on ENMs in order to engage 
stakeholders and concerned communities in the project.[30] Because of the diverse factors involved 
(environment, economy, health, industry), which are not necessarily compatible, it is difficult to build 
effective, coherent communication among all stakeholders. Conflicting interests in the ENM field reflect 
the many expectations and fears about the emerging nature of ENMs.[11] On the one hand there is concern 
that even discussion of potential health effects of ENMs will hinder development of the technology. On the 
other hand economic forecasts for development of ENM-related industries enhance the general and 
scientific mistrust of ENMs because their growth appears to be a forgone conclusion. In addition, given the 
many data gaps regarding workplace exposures and likely health effects, one concern is that the expanding 
development, production, and use of ENM could be “a large and largely uncontrolled asbestos-experiment 
with very long term consequences engaging increasing numbers of workers across the globe.”[25] Conflict 
of interests are both the cause and the consequence of the debate surrounding the precautionary principle 
application with regard to ENMs. The non-uniformity of precautionary principle definition, particularly 
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when it applies to ENM production, use and release[31], nourishes the division between “those who want 
to innovate quickly at all costs and those who want to think about the consequences first”[32].  The decision 
making on this subject is politically and ideologically influenced and remains challenging[31]. Although 
the precautionary principle is a general principle of the European Commission (EC) law, relied on the 
provision for the protection of both consumers (Art 153 EC Treaty) and the environment (Art. 174 EC 
Treaty), applying that, in balancing the conflicting interests, consumer interests should overweigh economic 
interests when negative effects on human health are at stake [33], the requirement of the appropriate 
labeling, informing the consumer about the use of ENMs in certain products (e.g., food and cosmetic 
products) is very challenging to enforce [33 34]. Putting aside the most severe option of precautionary 
principle, requiring bans on ENMs until they are shown to be safe (“No data, no market”), even its softer 
options including: 1-demanding labeling, 2-insisting the government agencies be notified when products 
contain particular ENM, and 3-taking steps to minimize human or environmental exposure until they have 
received further testing are challenging to achieve[34 35].  
For many companies, the information required for registration of ENMs and follow-up of ENM-exposed 
workers is considered confidential technical or commercial information, and sharing it would be detrimental 
to competition.[6] Companies’ reluctance about epidemiology and health surveillance could also be 
explained by the desire to avoid unsuitable responses and expenses that might be triggered by false alarms 
from inconsistent or clinically doubtful results.[36]  ENM exposure registration and health monitoring 
within a company may lead to unfounded employee expectations and to misuse of collected data if it were 
diverted for ethically unacceptable purposes (such as giving up a job or leaving employment for perceived 
health reasons).[25 36] Therefore, current epidemiological studies are for exploratory research rather than 
occupational health monitoring and should be carried out as such, despite the additional logistical efforts 
and communication necessary for their acceptance by participants.   
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Although voluntary participation raises a selection bias concern, mandatory participation may also prove 
ineffective. For example, the EpiNano program, based on a vigorous, mandatory obligation to declare 
ENMs in France since 2013 (R-nano), classified 64 of 127 companies that declared TiO2-nanoparticles or 
carbon nanotubes in 2015 as ineligible, and the data declared by the eligible companies did not make it 
possible to identify exposed workers or to estimate their exposure even qualitatively.[21 24] Corporate 
engagement will require discussions with  companies represented in the program consortium, as well as 
labor, governmental public health, and research organizations.[30] Multisource project funding is also, at 
least for large companies, an element to consider.[2] However, the cooperation of research bodies, public 
authorities, and companies is not easy to achieve logistically, and sometimes it is deemed unacceptable with 
respect to the Charter of Independence. In the case of ENMs, it would be essential to create a climate of 
trust and mutual commitment, backed up by a steering committee and rigorous collaborative research 
protocol,  allowing access to company data. Moreover, because of the small number of ENM-exposed 
workers in individual companies, scientific and political coordination at the national or even international 
level, as well as at the professional field level, is necessary in order to harmonize the research and collection 
protocols upstream of data collection.[14 16] To this end, the creation of a specific resource fund seems 
fundamental.[2 37] Yet, of the funds dedicated to research on ENM at the European level, so far none has 
been designated to finance this effort. Compared with research and technological development funding, 
environmental, health and safety research funding for nanotechnology was only 2.3%[38]. No 
epidemiological project has benefited from European or international funding, which clearly explains why 
only small, cross-sectional studies have been carried out so far. National governmental funding, although 
essential, is insufficient for raising awareness, and recruiting companies for a sufficiently long period to 
allow the forming of a large cohort of ENM-exposed workers. In France, an allocation from the Ministry 
of Health for the EpiNano program was limited to a 3-year recruitment of companies. This funded effort 
enabled the registration of 150 workers potentially exposed to carbon nanotubes and TiO2 
nanoparticles,[21] instead of the 1,500 workers initially expected.[12 39] In the United States, where more 
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than 100 workers exposed to carbon nanotubes have been identified in 14 companies and provided clinical 
examinations, currently available national funding is sufficient for only a cross-sectional study.[40] 
Many scientists internationally are ready for collaborations to enable searching for methodological and 
technical solutions for evaluating exposures and identifying workers potentially exposed in certain 
professional sectors.[14 16 22 39] Among other efforts, a roadmap toward a globally harmonized approach 
for occupational health surveillance and epidemiological study of nanomaterial workers, established in 
2012,14 has enabled researchers to achieve some progress in the last 5 years (Table 1). Moving forward 
requires strong political and corporate support and dedicated funding to establish collaborative research 
projects at national and international levels.  
CONCLUSION 
Nanotechnology and resulting ENMs represent an emerging and therefore unclear potential risk to human 
health. Studies of ENM effects on human health face many issues: practical issues such as the temporality 
of nanotechnology development and penetration into everyday life and consumer products; scientific issues 
requiring fundamental and applied research to characterize and classify the different ENMs according to 
their toxicity; methodological issues in measuring individual exposure to ENMs and investigating their 
specific medium- and long-term health effects through prospective follow-up; and political and regulatory 
issues. At present, the last seem to be the most challenging. Their resolution through concerted action, 
supported by scientific input from public health agencies capacities, and specific funding at the national 
and international levels should certainly facilitate the establishment of a multidisciplinary consortium 
promoting epidemiological research in a coordinated way. 
 
DISCLAIMER: The findings and conclusions in this report are those of the authors and do not necessarily 
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Box 1. Some definitions of nanomaterials and related terms legally accepted 
International Organization for Standardization (ISO):   
“Nano-objects, and their aggregates and agglomerates greater than 100 nm (NOAA) can exhibit 
properties, including toxicological properties, which are different from those of non-nanoscale (bulk) 
material” (ISO/TS 80004-2:2015);  
“Nanoscale is the size range from approximately 1-100 nm” (ISO/TS 27687:2008);  
“Nanomaterial is a material with any external dimension in the nanoscale or having internal structure or 
surface structure in the nanoscale” (ISO/TS 80004-1: 2010);   
“Aggregate is a particle comprised of strongly bonded or fused particles where the resulting external 
surface area may be significantly smaller than the sum of calculated surface areas of the individual 
components” (ISO, 2008); 
“Agglomerate is a collection of weakly bound particles, or aggregates or mixtures of the two, and for 
which the resulting external surface area is similar to the sum of the surface areas of the individual 
components (ISO, 2008);  
European Commission, Recommendation on the Definition of Nanomaterials: 
“Nanomaterial means a natural, incidental or manufactured material containing particles, in an 
unbound state or as an aggregate or as an agglomerate and where, for 50% or more of the particles in 
the number size distribution, one or more external dimensions is in the size range 1 nm -100 nm.” “In 
specific cases and where warranted by concern for environment, health, safety or competitiveness the 
number size distribution threshold of 50% may be replaced by a threshold between 1 and 
50%.”(Recommendation n. 696/2011) 
[In 2014, Norwegian Environment Agency and Danish Ministry of the Environment adopted this 
definition as regulatory definition] 
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European Parliament and the Council of the European Union on the provision of food information 
to consumers: 
“Engineered nanomaterial means any intentionally produced material that has one or more dimensions 
of the order of 100 nm or less or that is composed of discrete functional parts, either internally or at the 
surface, many of which have one or more dimensions of the order of 100 nm or less, including 
structures, agglomerates or aggregates, which may have a size above the order of 100 nm but retain 
properties that are characteristic of the nanoscale; 
“Properties that are characteristic of the nanoscale include: (i) those related to the large specific surface 
area of the materials considered; and/or (ii) specific physico-chemical properties that are different from 
those of the non-nanoform of the same material.” (EC, 2011) 
European Commission. Cosmetics Directive: 
“Nanomaterial means an insoluble or biopersistant and intentionally manufactured material with one or 
more external dimensions, or an internal structure, on the scale from 1 to 100 nm.” (EC, 2009) 
European Commission, Biocides Directive: 
“Nanomaterial means a natural or manufactured active substance or non-active substance containing 
particles, in an unbound state or as an aggregate or as an agglomerate and where, for 50% or more of 
the particles in the number size distribution, one or more external dimensions is in the size range 1-100 
nm. Fullerenes, graphene flakes, and single wall carbon nanotubes with one or more external 
dimension below 1 nm shall be considered as nanomaterials.” (EC, 2012) 
French Ministry of Ecology, Sustainable Development and Energy:  
“Substance at nanoscale is intentionally produced at nanometric scale, containing particles, in an 
unbound state or as an aggregate or as an agglomerate and where, for a minimum of 50% of particles in 
the number size distribution, one or more external dimensions is in the size range 1 nme100 nm. By 
derogation from this definition, fullerenes, graphene flakes and single-wall carbon nanotubes with one 
or more external dimensions below 1 nm are considered as substances at nanoscale.” (ANSES, 2012) 
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Table 1. Progress achieved following the establishment of a roadmap toward a globally harmonized 
approach for occupational health surveillance and epidemiological study of nanomaterial workers in 
2012. [14]  
Roadmap element Progress 
achieved 
Comments 
Exposure assessment 
  
Qualitative description of exposure and 
context 
Yes Many reports (EU, USA, ISO*) 
 
NECID** Ontology 
Identify emission sources and exposure 
types 
Yes Various papers but patchwork 
Measure exposure parameters Yes Slow but steady flow of research articles 
Identify descriptors for modelling Yes Models exist but are not ready for everyday 
use 
Strategy to feed an exposure registry Some Strategy is established (NECID), but actual 
data are not yet gathered 
Hazard assessment 
  
Identify potential pathophysiological 
mechanisms 
Some Many toxicity tests done 
 
Novel nano-bio-interactions not fully 
established, especially in relation to human 
pathophysiology 
Find markers for short-term health effects Yes Many useful markers, but they are not 
specific to nanomaterials or to nano-specific 
pathways or diseases 
Find markers for long-term health effects Yes Many useful markers, but they are not 
specific to nanomaterials or to nano-specific 
pathways or diseases 
Strategy to feed occupational health 
databases 
No Researchers and countries work in isolation 
Epidemiology and Risk Assessment & 
Management  
  
Propose adequate epidemiological designs Limited Traditional approaches only partially  fit for 
purpose 
Set up exposure and health effect registries Limited Some national efforts in USA and France 
Identify different risk assessment and 
management cultures 
No  
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Identify different data collection and 
protection philosophies 
No 
 
*International Organization for Standardization. **Nano Exposure & Contextual Information Database  
(http://www.perosh.eu/development-of-a-nano-exposure-and-contextual-information-database-necid) 
 
